Company: ARTL
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001640334-25-002022
Chunk: 14

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
M, or group of decision makers, in determining how to allocate resources in evaluating performance. The Company consists of a single reporting segment: life science. The life science segment is comprised of the Company’s development of therapeutics that target lipid-signaling modulation pathways, including the ECS, a network of receptors and neurotransmitters that form a biochemical communication system throughout the body. The Company’s CODM is its chief executive officer. 

 11Table of Contents

The accounting policies of the life science segment are as described in the summary of significant accounting policies. The CODM evaluates the performance of the life science segment based on the Company’s net loss as reported on the income statement as consolidated net loss. The Company’s segment assets are reported on the balance sheet as its total consolidated assets. The Company has not generated any revenue since its inception and expects to continue to incur losses into the foreseeable future as it continues to conduct research and development related activities through all stages of product development and clinical trials and subsequently seek approval from the respective regulatory authorities. The Company’s CODM utilizes cash forecast models to determine the Company’s investment in the life sciences segment. These models are reviewed regularly to monitor the Company’s operating results and performance and compared to the Company’s cash-based forecasts.   Three Months Ended   September 30,   2025  2024 General and administrative      Employee and director compensation $229  $228 Stock-based compensation  240   135 Professional fees  1,013   181 Other general and administrative (a)  332   326 Total general and administrative $1,814  $870    Nine Months Ended   September 30,   2025  2024        General and administrative      Employee and director compensation $700  $702 Stock-based compensation  440   408 Professional fees  2,050   734 Other general and administrative (a)  898   935 Total general and administrative $4,088  $2,779    Three Months Ended   September 30,   2025  2024        Research and development      Employee compensation $267  $157 Stock-based compensation  188   74 Professional fees  262   1,137 Other research and development (b)  558   (1,043)Total research and development $1,275